Stand Up To Cancer - standuptocancer.orgThis is where the end of cancer begins
   Please leave this field empty

In The News

Share this:

Like this page on Facebook

SU2C-supported Research Yields New Insights Into Melanoma

Scientists on the SU2C-Cancer Research Institute Immunology Dream Team and the SU2C-Melanoma Research Institute Melanoma Dream Team have separately reported findings that provide new insights into melanoma, the deadliest form of skin cancer. More than 75,000 cases of melanoma, and more than 10,000 deaths, are reported in the United States every year. While the new immunotherapy drugs are highly effective against melanoma in some patients (like former President Jimmy Carter), they are not effective in all cases. An SU2C-supported team at UCLA has reported findings on its research into the mechanisms of resistance which could lead to more effective immunotherapy.

+ More

Allison Named to Time’s List of 100 Most Influential People

James P. Allison, PhD, leader of the SU2C-Cancer Research Institute Cancer Immunology Dream Team, has been named to Time Magazine's list of the 100 "most influential people in the world" for his pioneering work in cancer immunology.

+ More

World Renowned Medical Oncologist Named Head of the Division of Solid Tumor Oncology

Dr. Diaz, Team Leader of the SU2C-Colorectal Cancer Dream Team: Targeting Genomic, Metabolic and Immunological Vulnerabilities of Colorectal Cancer, has been named Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering

+ More

SU2C Innovative Research Grant recipient leads research on melanoma vaccines

Catherine Wu, MD, of Dana-Farber Cancer Institute, who received an SU2C Innovative Research Grant (IRG) in 2011, is developing vaccines to help keep melanoma from returning in patients after surgery, according to Science magazine. Findings from the study were presented at the 2017 Annual Meeting of the American Association for Cancer Research (AACR). Dr. Wu's team sequenced the DNA from the patients' tumors and used computational methods to create a personalized vaccine intended to stimulate the immune system to attack returning cancer cells, Science said. The vaccines appear to have prevented early relapse in 12 patients with melanoma, reported the magazine, which is published by the prestigious American Association for the Advancement of Science (AAAS).

+ More

SU2C Scientist Explains How TGen Could Take the Pain out of Cancer

Thanks to SU2C Dream Team Leader Dr. Daniel Von Hoff's clinical leadership, TGen is becoming a bigger player in precision medicine. Clinical trials for rare and common cancers are available for patients in Arizona, while working to gain approval by the FDA.

+ More

Innovate Collaborate Accelerate